Recursion appoints Najat Khan as Chief R&D and Commercial Officer, joins board

RECURSION PHARMACEUTICALS, INC.

Dr. Khan appointed Chief R&D Officer and Chief Commercial Officer; also elected Class II Director with term through 2026.
Compensation: base salary $570k, target bonus 50% of base, sign-on bonus $500k, initial equity grant $8M (half RSUs, half options, 4-yr vest).
Previously Chief Data Science Officer at J&J; will lead R&D and build commercial capabilities at Recursion.
Board expanded from 8 to 9 members; no related-party transactions requiring disclosure.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Najat Khan

Class II Director

RXRX · RECURSION PHARMACEUTICALS, INC.

Effective: 2024-04-16
Filed: April 16, 2024, 7:59 PM ET

increased the number of members of the Board from 8 to 9 and elected Najat Khan, Ph.D., as a Class II Director of the Board, effective April 16, 2024

Appointed

Najat Khan

Chief Research and Development Officer and Chief Commercial Officer

RXRX · RECURSION PHARMACEUTICALS, INC.

Filed: April 16, 2024, 7:59 PM ET

On April 16, 2024, the Company announced that Dr. Khan will be its Chief Research and Development Officer and Chief Commercial Officer, effective upon commencement of her employment with the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Najat Khan was elected as Class II Director at RECURSION PHARMACEUTICALS, INC..

Action: elected
Role: Class II Director

Exact text from the filing

increased the number of members of the Board from 8 to 9 and elected Najat Khan, Ph.D., as a Class II Director of the Board, effective April 16, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Najat Khan was appointed as Chief Research and Development Officer and Chief Commercial Officer at RECURSION PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Research and Development Officer and Chief Commercial Officer

Exact text from the filing

On April 16, 2024, the Company announced that Dr. Khan will be its Chief Research and Development Officer and Chief Commercial Officer, effective upon commencement of her employment with the Company.

View on SEC.gov

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001601830-24-000035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.